



上海源叶生物科技有限公司
 Shanghai yuanye Bio-Technology Co., Ltd
 电话: 021-61312973 传真: 021-55068248
 网址: www.shyuanye.com
 邮箱: shyysw@sina.com

产品名称: **YHO-13351**
 产品别名: **YHO-13351**

生物活性:																											
Description	<p>YHO-13351 is the water-soluble prodrug of YHO-13177, which is a potent and specific inhibitor of BCRP. IC50 value: Target: BCRP inhibitor in vitro: YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. In addition, YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. In contrast, it had no effect on P-glycoprotein-mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells and multidrug resistance-related protein 1-mediated doxorubicin resistance in MRP1-transfected human epidermoid cancer KB-3-1 cells. YHO-13177 increased the intracellular accumulation of Hoechst 33342, a substrate of BCRP, at 30 minutes and partially suppressed the expression of BCRP protein at more than 24 hours after its treatment in both HCT116/BCRP and A549/SN4 cells [1]. in vivo: In mice, YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration. Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRP-transduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models [1].</p>																										
	<p>In Vitro: DMSO : * "≥" means soluble, but saturation unknown.</p> <table border="1"> <thead> <tr> <th rowspan="2">Preparing</th> <th>Solvent</th> <th>Mass</th> <th rowspan="2">1 mg</th> <th rowspan="2">5 mg</th> <th rowspan="2">10 mg</th> </tr> <tr> <th colspan="2">Concentration</th> </tr> </thead> <tbody> <tr> <td rowspan="3">Stock Solutions</td> <td>1 mM</td> <td></td> <td>1.7249 mL</td> <td>8.6247 mL</td> <td>17.2494 mL</td> </tr> <tr> <td>5 mM</td> <td></td> <td>0.3450 mL</td> <td>1.7249 mL</td> <td>3.4499 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.1725 mL</td> <td>0.8625 mL</td> <td>1.7249 mL</td> </tr> </tbody> </table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液, 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。 -80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。</p>				Preparing	Solvent	Mass	1 mg	5 mg	10 mg	Concentration		Stock Solutions	1 mM		1.7249 mL	8.6247 mL	17.2494 mL	5 mM		0.3450 mL	1.7249 mL	3.4499 mL	10 mM		0.1725 mL	0.8625 mL
Preparing	Solvent	Mass	1 mg	5 mg		10 mg																					
	Concentration																										
Stock Solutions	1 mM		1.7249 mL	8.6247 mL	17.2494 mL																						
	5 mM		0.3450 mL	1.7249 mL	3.4499 mL																						
	10 mM		0.1725 mL	0.8625 mL	1.7249 mL																						
Solvent&Solubility																											
References	<p>[1]. Yamazaki R, et al. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo. Mol Cancer Ther. 2011 Jul;10(7):1252-63.</p>																										